Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v1-EN
Language English English
Date Updated 2021-05-13 2021-03-25
Drug Identification Number 02330695 02330695
Brand name ERAXIS ERAXIS
Common or Proper name ERAXIS ERAXIS
Company Name PFIZER CANADA ULC PFIZER CANADA ULC
Ingredients ANIDULAFUNGIN ANIDULAFUNGIN
Strength(s) 100MG 100MG
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 30mL vial 30mL vial
ATC code J02AX J02AX
ATC description ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-04-16
Actual start date 2021-04-01
Estimated end date 2021-05-14
Actual end date 2021-05-12
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments
Health Canada comments